Jun 01, 2021 / 02:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Well, good morning, everyone, and welcome to another great session here at the 2021 Jefferies Global Healthcare Conference. I'm really excited to have my first fireside chat with Allogene Therapeutics. With us here, we have the Co-Founder, President and CEO, David Chang.
Now importantly, he just came off a really important data, preempting that ASCO conference what was important data. So maybe we could just take a step back, David, and maybe just talk about the development of 501A as an allogeneic CD19 CAR T and what was so impressive about this data in your mind that should get people excited that you just presented.
Questions and Answers:
David D. Chang - Allogene Therapeutics, Inc. - Co-Founder, President, CEO & DirectorFirst of all, Mike, thank you very much for hosting Allogene. It's been a little while since you and I were in the firechat, so it's a real pleasure to be together again. So given the time consideration, I'm going to be very quick on some of the
Trustpilot
